Literature DB >> 23295643

Drug updates and approvals: 2012 in review.

Jennifer M Belavic1.   

Abstract

Each year, the FDA approves many pharmaceuticals and products designed to treat or improve a patient's condition. The following is a sampling of some of the most important drugs approved in 2012 that specifically apply to nurse practitioner practice.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23295643     DOI： 10.1097/01.NPR.0000425824.44694.e8

Source DB:  PubMed          Journal:  Nurse Pract        ISSN： 0361-1817


  5 in total

1.  Biotransformation of Cobicistat: Metabolic Pathways and Enzymes.

Authors:  Pengcheng Wang; Amina I Shehu; Ke Liu; Jie Lu; Xiaochao Ma
Journal:  Drug Metab Lett       Date:  2016

Review 2.  Ranibizumab for the treatment of degenerative ocular conditions.

Authors:  Magdalini Triantafylla; Horace F Massa; Doukas Dardabounis; Zisis Gatzioufas; Vassilios Kozobolis; Konstantinos Ioannakis; Irfan Perente; Georgios D Panos
Journal:  Clin Ophthalmol       Date:  2014-06-24

3.  Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV--Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015.

Authors:  Robert S Rosenson; Lisandro D Colantonio; Greer A Burkholder; Ligong Chen; Paul Muntner
Journal:  J Am Heart Assoc       Date:  2018-12-18       Impact factor: 5.501

4.  LC-MS/MS determination of avanafil and its metabolites in rat plasma and brain: pharmacokinetic study after oral administration and transdermal film application.

Authors:  Ahmed K Kammoun; Alaa Khedr; Osama A A Ahmed
Journal:  RSC Adv       Date:  2020-03-04       Impact factor: 4.036

5.  Effects of selective and non-selective glucocorticoid receptor II antagonists on rapid-onset diabetes in young rats.

Authors:  Jacqueline L Beaudry; Emily C Dunford; Trevor Teich; Dessi Zaharieva; Hazel Hunt; Joseph K Belanoff; Michael C Riddell
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.